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Case report: massive postpartum
transfusion of Jr(a+) red cells in
the presence of anti-Jra
S.YUAN, R.ARMOUR,A. REID, K.F.ABDEL-RAHMAN, M. PHILLIPS, D.M. RUMSEY,AND T. NESTER
Jra is a high-prevalence antigen. The rare Jr(a–) individuals can form
anti-Jra after exposure to the Jra antigen through transfusion or
pregnancy. The clinical significance of anti-Jra is not well
established. This study reports a case of a 31-year-old woman with
a previously identified anti-Jra who required massive transfusion of
RBCs after developing life-threatening postpartum disseminated
intravascular coagulopathy. Despite the emergent transfusion of 15
units of Jra untested RBCs, she did not develop laboratory or clinical
evidence of acute hemolysis. The patient’s anti-Jra had a
pretransfusion titer of 4 and a monocyte monolayer assay (MMA)
reactivity of 68.5% (reactivity > 5% is considered capable of
shortening the survival of incompatible RBCs). The titer increased
fourfold to 64 and the MMA reactivity was 72.5% on Day 10
posttransfusion. Review of laboratory data showed evidence of a
mild delayed hemolytic transfusion reaction by Day 10
posttransfusion. Despite rare reports of hemolytic transfusion
reactions due to anti-Jra in the literature, most cases, including this
one, report that this antibody is clinically insignificant or causes
only mild delayed hemolysis. Clinicians should be advised to
balance the risks of withholding transfusion with the small chance
of significant hemolysis after transfusion of Jr(a+) RBCs in the
presence of anti-Jra. Immunohematology 2005;21:97–101.
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Jra is a high-prevalence antigen in all populations.
The Japanese population has the highest frequency of
the Jr(a–) phenotype. However, even in that
population, the incidence is reported to be only 0.03 to
0.12 percent.1 Because of its rarity, the clinical
significance of anti-Jra is not well established. Reid and
Lomas-Francis2 describe anti-Jra as being capable of
causing decreased RBC survival. In the obstetric
setting, the authors note that although the DAT can be
positive, anti-Jra is not associated with HDN.
Jr(a+) RBCs have been transfused to individuals
with anti-Jra without incident.3–5 On the other hand,
there exist in the literature a dozen or so reports
highlighting the ability of anti-Jra to cause both mild to
moderate HDN and delayed hemolytic transfusion
reactions.6 The typical hemolytic reaction associated
with anti-Jra is delayed, extravascular, and self-limited,
and the decreasing Hct is usually accompanied by
transiently increased antibody titers.7 More recently,
Kwon et al.6 reported a case of anti-Jra causing acute
hemolysis. In this report, we describe the case of a
patient with anti-Jra who developed postpartum
disseminated intravascular coagulopathy (DIC) and
received 15 units of incompatible Jr(a+) RBCs.
Subsequently she had no overt clinical signs of
hemolysis, and laboratory findings suggested only mild
delayed hemolysis.
Case Report
A 31-year-old multiparous Vietnamese woman with
history of three previously uncomplicated pregnancies
(with a different partner from the current pregnancy)
presented for prenatal care at an outside facility in the
32nd week of her fourth pregnancy. ABO/D typing
showed the patient’s RBCs to be Group A, D+. The
antibody screen test showed that the patient’s serum
reacted weakly with all reagent RBCs in the
antiglobulin phase of testing. RBC treatment using
either DTT or ficin had no effect on reactivity. The
autologous control and DAT were negative; thus an
antibody directed at a high-prevalence antigen was
suspected. The patient’s serum was then tested with
several RBC samples lacking various high-prevalence
antigens, including k, Kpb, and Ch, and RBCs with very
weak U expression. All RBCs tested reacted with the
patient’s serum. The specimen was subsequently
referred to our laboratory, where phenotyping of the
patient’s RBCs for high-prevalence antigens showed
that her RBCs possessed Vel,Dib,k,and Kpb antigens but
lacked Jra antigens. Jr(a–) RBCs from two different
donors located through Serum Cells and Rare Fluids
Exchange (SCARF) were not agglutinated by the
patient’s serum, which was consistent with the
presence of anti-Jra. Allogeneic adsorptions were
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performed with W.A.R.M-treated RBCs (W.A.R.M.;
Immucor Inc., Norcross, GA) that were also
phenotypically matched for Rh and Kidd antigens. No
additional alloantibodies were detected in the serum.
The anti-Jra was shown to have a titer of 4. Because of
the difficulty in locating Jr(a–) RBCs,and the possibility
of shortened survival of transfused Jr(a+) RBCs, we
recommended autologous donation or screening family
members in the hope of finding a compatible donor if
there was a reasonable concern that the patient or the
baby might need transfusion during the pregnancy and
delivery.
The patient went into labor during the 38th week
of her pregnancy and vaginally delivered a healthy male
infant without evidence of HDN. Her postpartum
course was complicated by development of DIC and
profuse, life-threatening vaginal bleeding, which
necessitated an emergent abdominal hysterectomy.
Intraoperatively, she received four units of uncross-
matched Group O,D– RBCs and 11 units of crossmatch-
incompatible Group A, D+ RBCs. Because of the high
incidence of Jra, all of the RBC units were presumably
Jr(a+). Her hemorrhage was eventually brought under
control after the surgery. Clinically, there was no
evidence of acute intravascular hemolysis during the
resuscitation effort.
Approximately 15 days after the initial surgery, the
patient was found to have developed abdominal
abscesses. Because surgery with possible significant
blood loss was anticipated, and because of the case
report from Kwon et al.6 reporting acute hemolysis
after repeated exposures to Jr(a+) RBCs, two frozen
units of Jr(a–) RBCs were imported from Blood Bank of
Hawaii. Of note, the only other possible source of units
of Jr(a–) RBCs at that time was from Japan. However,
these units would not have been immediately available
and would not have been fully tested for transfusion-
transmissible diseases according to FDA guidelines.
Initial attempts at computerized tomography–guided
drainage of the abscesses were complicated by
perforation of the colon. This necessitated a laparo-
tomy for hemicolectomy and abscess drainage. Both
units of Jr(a–) RBCs were transfused intraoperatively
without incident. The patient did not require further
transfusions. Twelve days after the second surgery, her
Hct was stable at 36.8%.
Materials and Methods
Antibody detection and identification were
performed by tube method. Antibody detection tests
were performed using reagent RBCs (Immucor, Inc.).
Antibody identification was performed using panels of
reagent RBCs (Ortho-Clinical Diagnostics, Inc., Raritan,
NJ, and Immucor, Inc.). Panels of ficin-treated RBCs
(Immucor, Inc.) were also used. DTT-treated RBCs
were prepared using 0.2 M solution (DTT, Sigma-
Aldrich Corp., St Louis, MO). Alloadsorption was
performed using W.A.R.M.-treated RBCs (W.A.R.M.;
Immucor, Inc.), which were also phenotypically
matched for Rh and Kidd antigens.
Polyspecific and monospecific DATs were
performed (Bioclone Anti-IgG, Bioclone Anti-C3d, and
Bioclone AHG, Ortho-Clinical Diagnostics) by standard
tube method. The elution was performed using the
rapid acid method (Elukit II, Gamma Biologicals, Inc.,
Houston,TX). Two different enhancement media (PEG,
Gamma Biologicals, and O.A.E.S., Ortho-Clinical
Diagnostics) were used to enhance antibody
agglutination. Antibody titer was determined with
serial dilutions of patient’s serum using IAT.
Patient’s RBCs were phenotyped using
conventional methods for the common antigens. Rare
antisera and reagent RBCs were prepared in-house or
provided through SCARF. Monocyte monolayer assay
(MMA) was performed by the American Red Cross
Blood Services of Southern California Region, Los
Angeles,California. The method was described in detail
elsewhere.8
Results
Anti-Jra was not detectable in the serum
immediately after the transfusion of the 15 units of
uncrossmatched (presumably Jr[a+]) RBCs. This was
not surprising because of the large volume of crystalloid
solutions and blood components administered during
the resuscitation. The DAT using polyspecific anti-
human globulin at this time was weakly positive (1+),
but the patient’s RBCs were negative in the DAT using
anti-C3d or anti-IgG. An eluate was performed and
tested and found to contain anti-Jra. Allogeneic
absorption of the eluate, using W.A.R.M-treated RBCs
that were also phenotypically matched for Rh and Kidd,
did not show any additional alloantibodies.
Because of the concern for a significant delayed
hemolytic transfusion reaction, we recommended that
the clinicians give intravenous fluids as necessary to
maintain adequate renal perfusion and monitor
laboratory values, including Hct, bilirubin, LDH, and
haptoglobin. Additionally, a sample was sent daily to
our reference laboratory for DATs and evaluation for
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hemolysis. The patient’s Hct decreased from 38.6% on
Day 5 posttransfusion to 30.9% on Day 10. Of note,
during this period the patient also developed
syndrome of inappropriate antidiuretic hormone
secretion and hyponatremia. The resulting fluid
retention and dilutional anemia contributed to the
decreasing Hct and made it unlikely that it was solely
due to hemolysis. On Day 10 posttransfusion, the total
bilirubin increased from 0.4 mg/dL at the time of
transfusion to 1.6 mg/dL (normal range 0.2–1.0 mg/dL)
and LDH increased from 307 to 431 IU/L (normal range
91–180 IU/L). Haptoglobin levels were obtained only
on Days 4 and 5 posttransfusion;both were well within
normal range. Anti-Jra became detectable in the serum
again on Day 6 posttransfusion and the titer had risen
from a pretransfusion titer of 4 to 64. Concurrently, the
reactivity of the polyspecific DAT increased from 1+ to
2+, and both the monospecific DATs (using anti-IgG
and anti-C3) reacted 2+ at 6 days posttransfusion. Both
the prenatal pretransfusion serum sample and a serum
sample obtained on Day 10 posttransfusion were sent
for MMA testing, which showed 68.5% and 72.5%
reactivity respectively (reactivity > 5% is considered
capable of shortening the survival of incompatible
RBCs). However, visual check of serial serum samples
showed no evidence of hemolysis, and the patient
continued to have no overt clinical evidence of
intravascular hemolysis during the posttransfusion
period. Select laboratory values are shown in Table 1.
Table 1. Results of select pertinent laboratory tests pretransfusion and in the days after massive transfusion of 15 units of presumably Jr(a+) RBCs in the
presence of anti-Jra.
Day Hct Na LDH Total bilirubin Anti-Jra
(posttransfusion) (%) (135–145 mmol/L)* (91–180 IU/L)* (0.2–1.0 mg/dL)* DAT titer Other lab values
–30 – – – – Negative 4 MMA reactivity:
(pretransfusion) 68.5% (≤ 5%)*
0 24 131 307 0.4 – – Prothrombin time = 36.5,
International normalized 
ratio = 3.53,
50.7 Partial prothrombin 
time =138.8
7.4 Fibrinogen = 72 mg/dL
D-dimer > 10,000 ng/mL
Platelet = 13 × 109/L
1 33.2 139 – 0.9 Polyspecific: 1w – –
anti-IgG: 0
anti-C3: 0
4 33.4 138 261 – – – Haptoglobin 121 
(43–212 mg/dL)*
5 38.6 125 333 – Polyspecific: 2+ Haptoglobin 101 
118 anti-IgG: 2+ (43–212 mg/dl)*
123 anti-C3: weak – Urine bilirubin negative
6† 38.2 123 391 – Polyspecific: 2+ 64 –
anti-IgG: 2+
anti-C3: 2+
8† 33.6 132 386 2.2 Polyspecific: 1+ 64 –
Direct 0.5 anti-IgG: 1+
anti-C3: 1+
10† 30.9 132 431 1.6 Polyspecific: 2+mf 64 MMA reactivity:
anti-IgG: 1+mf 72.5% (≤ 5%)*
anti-C3: 1w mf
15‡ 28.8 133 – – Polyspecific: 2+ – –
anti-IgG: 1+
anti-C3: 2+
17 25.2 132 372 0.7 – – Haptoglobin 201
Direct 0.1 (43–212 mg/dl)*
(0.0–0.2 mg/dL)* Urine bilirubin negative
20 30.0 128 – 0.6 – – –
27 36.8 134 – – – – –
*Normal range values
†Results from Days 6 to 10 show evidence of onset of mild delayed hemolysis. Visual checks of serum showed no evidence of hemolysis through this period.
‡On Day 15, patient underwent abdominal surgery and received two units of Jr(a–) RBCs intraoperatively.
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Discussion
Because of the rarity of anti-Jra, its clinical
significance is not clear. Several reports of anti-Jra
causing mild to moderate HDN9,10 exist in the literature,
but others have questioned the validity of the
diagnoses in such cases.11 Mild to moderate delayed
hemolytic transfusion reactions9,12,13 have also been
reported in association with anti-Jra. More recently,
Kwon et al.6 reported a concerning case of acute
hemolytic transfusion reaction due to this antibody in
the setting of repeated exposures to the antigen within
a week. On the other hand, others have reported no
clinical evidence of hemolysis after incompatible
transfusions, even in the face of rising antibody titers.4
Studies using monocyte phagocytosis14 and MMA8,15
suggested that most anti-Jra are not clinically
significant. The lack of clinical significance in most
cases could be in part accounted for by the low antigen
density of Jra on the RBC membrane.14,16
Additional data are needed to fully establish the
clinical significance of anti-Jra. The MMA has been
proposed as a valuable tool for predicting the clinical
significance of antibodies to high-prevalence antigens
such as anti-Jra.8,15 A recent retrospective review of 20
years of MMA data by Arndt and Garratty8 showed that
only results greater than 5% are potentially clinically
significant. Furthermore, one-third of patients with
MMA results between 5.1% and 20% had clinical signs of
hemolysis (defined as jaundice, fever, chills, change in
blood pressure, back pain, vomiting, tachypnea, and
hemoglobinuria8), and two-thirds of patients with MMA
results greater than 20% reactivity had such symptoms.
When clinical signs of hemolysis were absent, patients
from both groups often had laboratory indications of
hemolysis, which included decreased Hb, Hct, and
haptoglobin, increased bilirubin or LDH, hemo-
globinemia,or the presence of bilirubin in the urine. In
the same review, only 5 out of 14 (36%) cases of anti-Jra
examined showed MMA reactivity greater than 5%, two
of which had reactivity greater than 20%. But the
positive predictive value of the MMA result for
hemolysis is not established specifically for anti-Jra
because of the small number of cases and the lack of
associated clinical information. Through a personal
communication with these authors, we learned that
clinical information was available on 4 of the 15 cases.
Two of these cases had MMA results greater than 20%.
Of these, one experienced a transfusion reaction with
the infusion of a third unit of Jr(a+) RBCs. This is the
same case reported by Kwon et al.6 In the other case,
flow cytometry showed normal RBC survival compared
with the calculated expected RBC survival rate.
Clinically the patient did not have signs of hemolysis.
Clinical information on the other 11 patients is
unavailable. In our case, despite the strong MMA
reactivity both before and after the transfusion of a total
of 15 units of incompatible RBCs, we found no clinical
evidence of hemolysis and only laboratory evidence of
very mild, well-tolerated, delayed hemolysis. The
decrease in Hct was at least in part due to dilutional
anemia and postoperative surgical blood loss.
It is likely that most transfusions of Jr(a+) RBCs will
not result in significant acute or delayed hemolysis in
the presence of anti-Jra. However, because anti-Jra can
cause significant acute hemolysis at least in rare cases
after repeated exposures to Jr(a+) RBCs6, it is prudent
to make a reasonable attempt to locate Jr(a–) RBC units
when anti-Jra is identified,especially in those cases with
strongly positive MMA results. If blood loss can be
anticipated, as in the case of an elective surgery or
delivery, autologous donations should be encouraged.
It may also be necessary to look into family members
and rare donor registries as potential sources of
compatible units because of the extreme scarcity of the
Jr(a–) phenotype in North America. It is important to
weigh the availability of Jr(a–) RBCs against the cost
and the infectious disease risks when importing such
units from countries outside the United States or older
units frozen before the availability of the most current
infectious disease testing. In our opinion, the risks of
acquiring an infectious disease appear to outweigh the
risks of transfusing Jr(a+) units, and clinicians should
be guided in this way. Additionally, clinicians should be
advised of the available serologic results, which might
include antibody titer, DAT reactivity, and MMA results.
The limitations of these data and the lack of conclusive
information in the current literature regarding the
clinical significance of anti-Jra must be made clear as
well. The clinical decision to transfuse Jr(a+) RBCs and
the risks of hemolysis after transfusion of incompatible
RBCs must also be evaluated against the risks of
withholding transfusion. The recent guidelines of the
UK National Blood Service17 recommended transfusing
serologically least-incompatible RBCs to patients with
anti-Jra and antigen-negative RBCs to patients with
strong anti-Jra when transfusion is necessary. We feel
this approach is reasonable given the rarity of Jr(a–)
RBC units, the lack of data we have about anti-Jra, and
the lack of laboratory assays that can reliably predict its
clinical significance.
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